Researchers presented results from a simulation analysis that looked to identify the potential reduction in Medicare beneficiaries’ out-of-pocket costs through the use of biosimilar filgrastim-sndz (Zarxio, Sandoz) over the reference filgrastim at the 2018 San Antonio Breast Cancer Symposium held December 4-8, 2018, in San Antonio, Texas.
Researchers presented results from a simulation analysis that looked to identify the potential reduction in Medicare beneficiaries’ out-of-pocket costs through the use of biosimilar filgrastim-sndz (Zarxio, Sandoz) over the reference filgrastim at the 2018 San Antonio Breast Cancer Symposium held December 4-8, 2018, in San Antonio, Texas.
The analysis was based on data from more than 1600 claims and found that out-of-pocket expenditures were substantially less among Medicare beneficiaries with breast cancer undergoing chemotherapy who received prophylaxis for febrile neutropenia with biosimilar filgrastim over the reference product.
Researchers used ICD-10 codes to identify patients with breast cancer in this simulation, and Healthcare Common Procedure Coding System codes were used to identify those treated with filgrastim-sndz or the reference. The claims used in the simulation were extracted from the 2016 Medicare Limited Data Set. In total, the study authors extracted 233 claims for 300 mcg of biosimilar filgrastim (average price, $244.94) and 383 claims for 480 mcg of biosimilar filgrastim (average price, $421.15). Thus, the total number of included claims for filgrastim-sndz was 616, with a weighted average price of $362.79.
Conversely, 380 claims for 300 mcg of reference filgrastim were also extracted (average price, $283.92), and 684 claims for 480 mcg of reference filgrastim (average price, $478.32), for a total of 1064 claims at a weighted average price of $406.86.
In order to calculate the average Medicare payment to the provider and the average beneficiary out-of-pocket responsibility per claim for either product, researchers utilized Medicare’s payment calculation worksheet. According to the worksheet, beneficiaries were assumed to pay the provider 20% coinsurance; in the case of a secondary payer, the payment to the provider was 20% minus payment by the secondary provider.
Physicians were reimbursed by Medicare at 80% of the allowed cost for either product, with a 2% reduction calculated for prescriptions written during the sequestration period that began in 2013 and has continued ever since.
The total payment to the provider was found to be $221 for 300 mcg of filgrastim-sndz and $380 for 480 mcg of filgrastim-sndz, and $257 for 300 mcg of reference filgrastim and $433 for 480 mcg of reference filgrastim. Researchers found that the weighted average savings to Medicare for the use of filgrastim-sndz over the reference product was $32.87 per claim, reflecting the Medicare weighted average payments to providers of $284.06 and $316.93 per claim, respectively.
When extrapolated to 100,000 beneficiaries (1 million claims), the model estimated potential out-of-pocket savings to reach approximately $9.5 million for Medicare beneficiaries. Additionally, the study also found that Medicare saw reduced payments of $32.9 million.
“By weighted average, a beneficiary’s out-of-pocket responsibility for filgrastim-sndz was lower than that for reference filgrastim ($72.94 versus $82.45), creating a weighted average cost savings per claim of $9.51,” concluded the study authors.
Reference
Puckrein G, Xu L, Ryan A, et al. Potential Medicare beneficiary out-of-pocket cost reductions through use of biosimilar filgrastim-sndz over reference filgrastim among breast cancer patients: a simulation model analyses. Presented at: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. Abstract P5-15-05.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.